10-QPeriod: Q2 FY2022

INTUITIVE SURGICAL INC Quarterly Report for Q2 Ended Jun 30, 2022

Filed July 22, 2022For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported its financial results for the quarter and six months ended June 30, 2022. Total revenue for the quarter increased by 4% year-over-year to $1.52 billion, driven by a 12% increase in instruments and accessories revenue, largely due to a 14% rise in da Vinci procedures. However, systems revenue saw a 15% decline, impacted by fewer system placements and supply chain challenges. The company's installed base of da Vinci Surgical Systems grew by 13% year-over-year to 7,135 systems. For the six-month period, total revenue grew by 9% to $3.0 billion, with instruments and accessories revenue up 14% and service revenue up 12%, while systems revenue remained flat. The company continues to invest significantly in research and development, with R&D expenses increasing by 30% year-over-year for the six-month period, indicating a focus on future innovation. Despite revenue growth, operating income decreased by 22% for the quarter due to increased operating expenses, including higher selling, general, and administrative costs and research and development expenses.

Financial Highlights

45 data points
Beta

Revenue

$1.52B

67.2% Gross Margin

Net Income

$307.80M

20.2% Net Margin

EPS (Diluted)

$0.85

Total Assets

$13.71B

Cash & Equivalents

$1.55B

Free Cash Flow

$446.70M

Financial Statements
Beta
Revenue$1.52B
Cost of Revenue$498.80M
Gross Profit$1.02B
R&D Expenses$207.30M
SG&A Expenses$418.40M
Operating Expenses$625.70M
Operating Income$397.60M
Net Income$307.80M
EPS (Basic)$0.86
EPS (Diluted)$0.85
Shares Outstanding (Basic)358.10M
Shares Outstanding (Diluted)363.90M

Key Highlights

  • 1Total revenue for the three months ended June 30, 2022, increased 4% to $1.52 billion, driven by strong performance in instruments, accessories, and services.
  • 2Da Vinci procedures increased by 14% year-over-year in the second quarter of 2022, reaching approximately 465,000, indicating continued adoption and utilization of the da Vinci Surgical System.
  • 3Systems revenue saw a notable decrease of 15% to $375 million in the second quarter, attributed to a 15% decline in da Vinci Surgical System placements and challenges in the supply chain.
  • 4The company's installed base of da Vinci Surgical Systems grew 13% year-over-year to 7,135 systems as of June 30, 2022, demonstrating ongoing expansion.
  • 5Operating income decreased by 22% to $398 million in the second quarter, primarily due to a significant increase in operating expenses, including R&D and SG&A, as the company continues to invest in growth initiatives.
  • 6The company repurchased approximately $607 million of its common stock during the first six months of 2022, signaling a commitment to returning capital to shareholders.
  • 7While overall revenue shows growth, the company highlighted ongoing supply chain challenges and macroeconomic pressures, such as inflation and rising interest rates, impacting hospital capital spending and potentially future system demand.

Frequently Asked Questions

For the three months ended June 30, 2022, Intuitive Surgical reported total revenue of $1.52 billion, a 4% increase year-over-year. This growth was primarily driven by higher revenue from instruments, accessories, and services, fueled by a 14% increase in da Vinci procedures. However, systems revenue declined by 15%, impacting overall profitability, with operating income decreasing by 22% due to increased operating expenses.

The primary drivers for revenue growth are the increase in the number of da Vinci procedures performed (up 14% year-over-year for the quarter), which boosts revenue from instruments and accessories, and an increase in service revenue, largely due to a larger installed base of systems. The company's expanded installed base of da Vinci systems (up 13% year-over-year) supports this recurring revenue stream.

Intuitive Surgical highlighted significant challenges including ongoing global supply chain disruptions, particularly for semiconductor components, and logistical hurdles. Macroeconomic factors like inflation, rising interest rates, and hospital financial pressures are also noted as potential headwinds affecting capital spending and demand for systems. The company also mentioned the potential impact of the COVID-19 pandemic and geopolitical uncertainties.

The company utilized $607 million for share repurchases in the first six months of 2022, indicating active capital return to shareholders. The Board also increased the authorized repurchase program. As of June 30, 2022, the company held $8.18 billion in cash, cash equivalents, and investments, providing a strong liquidity position.